- cafead   Jun 07, 2023 at 09:52: PM
via Caribou Biosciences doesn't want to follow the leader as its cell therapy rival backs off to focus on relapsed patients with lymphoma. Instead, CEO Rachel Haurwitz, Ph.D., says the CRISPR-focused company is looking a few plays ahead.
article source
article source